$1.62−0.06 (−3.57%)
At close: Nov 16, 2026, 4:00 PM ET· Nasdaq · USD
Opko Health (OPK) Income Statement
Is this a real, growing, cash-generative business, or a story propped up by accounting?
Sources Company filings FilingsHow we compute thisNot investment advice
Business engineChoppy: revenue is 66% below its peak, net margin −37.2%. Worth your attention in FY25: Share count (+10.2%). Visible in the receipts below.
The four lines that matter · FY21–FY25
Revenue ($M)▼14.9%
606.9
FY21→FY25CAGR −23.5%/yr
Net income ($M)▼324.0%
−225.7
one-off year: see footnoteCAGR —
Free cash flow ($M)▲8.5%
−190.8
FY21→FY25CAGR —
Diluted EPS▼275.0%
−0.30
no value for 2 of 5 yearsCAGR —
What the receipts whisper · what a headline number hides
Share count
+10.2%
681.5mn → 751.1mn diluted shares since FY21. Rising share count dilutes EPS. Growth must outrun it.
Capex
$12.3M
−50.9% YoY in FY25 · 2.0% of revenue.
What the income statement says · FY21–FY25
Where every revenue dollar goes · FY25 ($M)
-37¢ of every revenue dollar becomes profit. The biggest cost lever is COGS.
Margin trend · direction beats level Gross Operating Net
Over this window: gross 32.8% → 33.9%. Net margin -37.2% is below the sector median.
The receipt · income statement · FY21–FY25 USD millions except per-share & ratios · hover a line for its definition
USD millions except per-share & ratios
| Line item | TTM † | FY25 | FY24 | FY23 | FY22 | FY21 | YoY | CAGR 21→25 |
|---|---|---|---|---|---|---|---|---|
| Revenue & profitability | ||||||||
Revenue | 596.9 | 606.9 | 713.1 | 863.5 | 1,004.2 | 1,774.7 | ▼14.9% | −23.5% |
Cost of revenue | 350.2 | 400.9 | 494.6 | 545.4 | 716.0 | 1,193.2 | ▼18.9% | −23.9% |
Gross profit | 246.7 | 205.9 | 218.5 | 318.1 | 288.2 | 581.5 | ▼5.8% | −22.9% |
Research & development | 127.6 | 124.0 | 105.2 | 89.6 | 73.9 | 76.8 | ▲17.9% | +12.7% |
Selling, general & admin | 208.4 | 223.0 | 304.2 | 300.6 | 372.7 | 468.9 | ▼26.7% | −17.0% |
Total operating expenses | 292.8 | 323.3 | 370.6 | 475.1 | 514.5 | 562.8 | ▼12.7% | −12.9% |
Operating incomefeeds ROC rank | −46.1 | −117.4 | −152.1 | −157.0 | −226.3 | 18.8 | ▲22.8% | — |
Other income, net | −30.6 | −124.0 | 141.7 | −27.3 | −165.3 | −32.8 | — | — |
Pretax income | −76.7 | −241.4 | −10.4 | −184.3 | −391.5 | −14.0 | ▼2229.3% | — |
Income tax | −6.2 | −15.7 | 42.8 | 4.4 | −63.5 | 15.5 | — | — |
Net incomePiotroski ROA ✕feeds Buffett Quality owner earnings | −148.1 | −225.7 | −53.2 | −188.9 | −328.4 | −30.1 | ▼324.0% | — |
| Per share | ||||||||
Diluted EPSbuyback-sensitive | −0.19 | −0.30 | −0.08 | −0.25 | — | — | ▼275.0% | — |
Diluted shares (mn) | 746.48 | 751.13 | 694.02 | 751.77 | 772.65 | 681.46 | ▲8.2% | +2.5% |
| Margins | ||||||||
Gross margin18th pct in Healthcare | 41.3% | 33.9% | 30.6% | 36.8% | 28.7% | 32.8% | ▲3.3pp | +1.2pp |
Operating margin | −7.7% | −19.3% | −21.3% | −18.2% | −22.5% | 1.1% | ▲2.0pp | −20.4pp |
Net margin18th pct in Healthcare | −24.8% | −37.2% | −7.5% | −21.9% | −32.7% | −1.7% | ▼29.7pp | −35.5pp |
† TTM = trailing four quarters through 2026-09-30.FY21 effective tax rate was −110% vs a −2% norm for this window, likely a one-time item; see the filing.FY22 effective tax rate was 16% vs a −2% norm for this window, likely a one-time item; see the filing.
5 more years of statements and CSV export are on Premium, and 12 more on Ultimate.Premium · $119/yr · 7-day trial · cancel anytimeUnlock with Premium →
These lines feed the tenet checklists: see which gates passTenets →Margins & returns continue as sector-ranked ratiosStatistics →
Annual report filed 2026-02-26 · view filings on SEC EDGAR ↗ · reported currency USD · as-filed figures may be later restated.
Statements normalized in our fundamentals DB · Not investment advice.
Statements normalized in our fundamentals DB · Not investment advice.
Common questions
What was Opko Health's revenue last fiscal year?
Opko Health reported revenue of $606.9M in fiscal 2025, down 14.9% from fiscal 2024.
What was Opko Health's net income?
Opko Health reported net income of −$225.7M in fiscal 2025, a net margin of −37.2%.
Annual and quarterly statements as filed, normalized into one comparable shape · Not investment advice.

